Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.
This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.
All pregnant women between the ages of 18-45 with a history of psychiatric illness are eligible to enroll in the registry. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy. We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants. For more information, please visit this page, call 1-866-961-2388 or e-mail email@example.com.
Course of ADHD in Pregnancy and the Postpartum
If you are less than 20 weeks pregnant and have a history of ADHD, you may be eligible to take part in an observational research study for women maintaining, decreasing, or discontinuing psychostimulants during pregnancy and the postpartum. Women who participate will have 6 study visits that can be completed in-person at Massachusetts General Hospital or over the phone.
For more information, please call (617)726-2912 or email the study coordinator at firstname.lastname@example.org
Are you pregnant or planning a pregnancy? Do you feel depressed or have a history of depression? If you are less than 28 weeks pregnant or trying to conceive and have experienced depression now or in the past, you may be eligible to take part in a research study for the treatment of depression with a prenatal supplement. For more information, please visit this page, call Taylor at 617-643-9284 or email email@example.com
Are you pregnant or planning to become pregnant? Do you have a history of depression? Do you want to lose weight or have a healthier lifestyle? You may be eligible to participate in a research study evaluating a new lifestyle intervention for weight loss. Participants will receive 10 sessions of therapy at no cost to you.
If you are interested in participating or would like additional information, please call Samantha at 617-643-2076.
The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Building
185 Cambridge St Suite 2200
Boston, MA 02114
To make an appointment:
Massachusetts General Hospital Clinical Program: (617) 724-7792
Location of appointments:
Wang Ambulatory Care Center, Massachusetts General Hospital
15 Parkman St., Floor 8
Boston, MA 02114-3117
May 16, 2018
Every day, we see women in our clinic who are deciding whether to continue a selective serotonin reuptake inhibitor (SSRI) for management of depression or anxiety during pregnancy. As a class, SSRI use during pregnancy is generally not associated with a significant overall risk for major congenital malformations. While we often do think about SSRIs as ...Read more
May 15, 2018
Hypoactive sexual desire disorder (HSDD) is the most common type of female sexual dysfunction, affecting approximately 10% of all adult women. In certain populations of women that we see in our clinic, including women treated with serotonergic antidepressants and perimenopausal women, rates of sexual dysfunction are even higher. Currently, flibanserin is the only medication approved ...Read more
May 9, 2018
Last year France banned the use of the antiepileptic during valproate in certain populations of reproductive age women. Now the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has banned the use of valproate in women of childbearing age unless they are enrolled in a pregnancy prevention program (PPP). From the initial report, it ...Read more
May 7, 2018
For those in the Boston area, this Wednesday May 9th is Perinatal Mental Health Awareness & Advocacy Day 2018. This event will be held at the Great Hall, Massachusetts State House at 24 Beacon St. in Boston from 12PM to 3PM. This is a free event for all who are interested in promoting awareness of perinatal ...Read more
May 7, 2018
The following post was first published in OB/GYN News. Please see our OB/GYN News archives here. Publish date: April 23, 2018 The last two decades have seen an ever-growing number of reports on risks of fetal exposure to medicines used to treat depression during pregnancy. These reports have described issues ranging from estimated risk of congenital malformations following fetal exposure ...Read more
May 7, 2018
When we meet with women reporting premenstrual symptoms, we often recommend that they avoid the use of alcohol. Analyzing 19 previously published studies of alcohol and PMS, researcher found that risk for PMS risk was 45% higher in women who reported drinking than in non-drinkers. Women who were heavy drinkers, drinking more than one drink ...Read more